Moderna (MRNA) faces competitive pressure in several markets as its COVID-19 vaccine share is projected to decline to 40% and uncertainties persist regarding respiratory syncytial virus recommendations and manufacturing plant licensure outside the US, Morgan Stanley said in a note Wednesday.
The company's plans to reduce operating costs to $5.5 billion in 2025 and to $5 billion in 2026 will require scaling back some early-stage programs and improving operational efficiency, according to the note.
Morgan Stanley said Moderna's pipeline progress remains critical and melanoma trial with Merck (MRK) is "likely the most significant opportunity," but developments in cytomegalovirus vaccine are an immediate focus.
Morgan Stanley reduced its revenue expectations for 2030/2035 to $5.5 billion/$7.8 billion from $7.9 billion/$10.9 billion due to lower sales for mRESVIA, SpikeVax and Covid+flu and removal of revenue from phenylketonuria pipeline program.
The brokerage lowered its price target on Moderna's stock to $38 from $70 with an equal-weight rating.
Price: 34.83, Change: +0.37, Percent Change: +1.06
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。